Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | RXRB | P28702 | 1/20 | 0.36 |
| ▸ | RXRG | P48443 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CES2 | O00748 | 2/20 | 0.34 |
| ▸ | KIF11 | P52732 | 5/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | PNMT | P11086 | 3/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22140446 | 0.86 | ALDH1A1 (0.31) | NOTUMGLAPOLBGAATSHR | |
| SCHEMBL12956782 | 0.86 | PDE2A (0.33) | NOTUMGLAPOLBGAATSHR | |
| SCHEMBL3534403 | 0.82 | GLA (0.54) | GLAPOLBGAATSHRPNMT | |
| SCHEMBL6058773 | 0.82 | NOTUM (0.35) | NOTUMGLAPOLBGAATSHR | |
| SCHEMBL3842171 | 0.82 | GLA (0.33) | NOTUMGLAPOLBGAATSHR | |
| SCHEMBL80848 | 0.80 | MPL (0.40) | KIF11 | |
| SCHEMBL29950533 | 0.80 | MPL (0.40) | KIF11 | |
| SCHEMBL79185 | 0.80 | KIF11 (0.48) | KIF11KDM1A | |
| SCHEMBL29453100 | 0.80 | KIF11 (0.48) | KIF11KDM1A | |
| SCHEMBL786516 | 0.78 | FFAR4 (0.40) | GLAPOLBGAATSHRKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2776398-B1 | SUBSTITUTED PYRAZOLYL-BASED UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | MEDIFRON DBT INC (KR) | 2020-09-02 | — | — | EP | disclosed |
| EP-3224252-B1 | SUBSTITUTED OXAZOLE- AND THIAZOLE-BASED CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS II | MEDIFRON DBT INC (KR) | 2019-01-09 | — | — | EP | disclosed |
| EP-2491022-B1 | DIAZEPAN DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | HOFFMANN LA ROCHE (CH) | 2014-12-31 | — | — | EP | disclosed |
| US-8445674-B2 | Heterocyclyl compounds | Hoffmann-La Roche Inc (US) | 2013-05-21 | — | — | US | disclosed |
| EP-2491022-A1 | DIAZEPAM DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | F. Hoffmann-La Roche AG (CH) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011048032-A1 | DIAZEPAM DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-28 | — | — | WO | disclosed |
| US-20110092698-A1 | NOVEL HETEROCYCLYL COMPOUNDS | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2011-04-21 | — | — | US | disclosed |
| WO-2007034282-A2 | DIARYL-IMIDAZOLE COMPOUNDS CONDENSED WITH A HETEROCYCLE AS C3A RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2007-03-29 | — | — | WO | disclosed |
| US-20020042541-A1 | Process for producing bis( trifluoromethyl)benzaldehyde | CENTRAL GLASS COMPANY, LIMITED (JP) | 2002-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042541-A1 | Process for producing bis( trifluoromethyl)benzaldehyde | BRPF1, PFAS, FLI1 | NOTUM 1207/4885RXRA 3895/4885RXRB 3094/4885 |
| US-20110092698-A1 | NOVEL HETEROCYCLYL COMPOUNDS | CCR2, CCR3, CCR1 | NOTUM 3780/4885RXRA 209/4885RXRB 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.